Atara Biotherapeutics, Inc. (ATRA) stock

ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$7.70−0.23 (-2.90%)

Close on Nov 13, 2026Market cap $77.29MP/E –Yield –

Atara Biotherapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Atara Biotherapeutics's price to book ratio was 0.7× on Apr 30, 2024, against 2.6× a year earlier. Over the last 5 years it ranged from 0.7× to 20.1×, with a median of 2.7×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2024	Apr 30, 2024	0.7×	−16.8
2023	Oct 31, 2023	17.5×	+15.8
2022	Dec 30, 2022	1.7×	−2.8
2021	Dec 31, 2021	4.5×	+0.2
2020	Dec 31, 2020	4.3×	+1.5
2019	Dec 31, 2019	2.8×	−1.1
2018	Dec 31, 2018	3.9×	+3.9
2017	Dec 29, 2017	0.0×	−1.5
2016	Dec 30, 2016	1.5×	−0.7
2015	Dec 31, 2015	2.2×	–

Where these numbers come from

Parsed from the XBRL in Atara Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Jun 20, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing